Brain Fog in Midlife: Separating Mechanism from Marketing

Walking into a room and forgetting why. Losing a word you use every day. Rereading the same paragraph three times. Women describe this in almost identical terms during their 40s and early 50s, and for a long time the standard response was some version of "it's stress" or "it's just getting older."

That response turned out to be partly wrong. There is now good longitudinal evidence that something measurable happens to cognition during the menopause transition. There is also good evidence about what that something is, how large it is, and how long it lasts. That evidence is considerably more reassuring than the worry it tends to produce, and considerably less useful to supplement marketing than the marketing would like.

This post covers what the research actually measured, what it points to as contributing factors, and how the most common "brain fog" products hold up against it.

"Brain fog" is a description, not a diagnosis

Start with the term itself. Brain fog is not a medical diagnosis. It has no diagnostic criteria, no agreed definition, and no test. Researchers studying it generally use the phrase subjective cognitive complaints, meaning what people report experiencing, and they measure it separately from objective cognitive performance, meaning what people actually score on standardized tests.

That distinction matters more than it sounds. A subjective complaint is real. It describes a genuine experience. But it doesn't tell you which mechanism is behind it, and very different causes can produce the same feeling. Poor sleep produces it. Anxiety produces it. Depression produces it. So can thyroid problems, anemia, certain medications, and plain overload. A product sold "for brain fog" is sold for a feeling, which means it can be marketed to almost anyone without claiming to treat anything specific.

What the best longitudinal data found

The most important research on this comes from the Study of Women's Health Across the Nation, known as SWAN, a multicenter, multiethnic, community-based study that has followed a large cohort of US women through the menopause transition.

The key analysis was published by Gail Greendale and colleagues in Neurology in 2009, volume 72, pages 1850 to 1857. They followed 2,362 women over four years and repeatedly tested three cognitive domains: processing speed using the Symbol Digit Modalities Test, verbal memory using the East Boston Memory Test, and working memory using Digit Span Backward. When cognitive testing began, the women's mean age was 50.

The design is worth understanding, because the finding depends on it. When people take the same cognitive test several times, they normally get better at it. This practice effect is expected in midlife and shows up reliably in healthy adults.

Here is what SWAN found. Women who were premenopausal, early perimenopausal, or postmenopausal improved with repeated administration of the processing speed test, with a p-value at or below 0.0008. Women in late perimenopause did not improve, with a p-value of 0.2. Verbal memory showed a similar perimenopausal decrement. And after the transition, improvement rebounded to premenopausal levels.

The authors concluded that perimenopause was associated with a decrement in cognitive performance, characterized by women not learning as well as they had before, and that these difficulties may be time-limited.

The detail that changes how this should feel

Read that finding carefully, because the popular version of it is not quite what the study showed.

A later progress report from the SWAN investigators, led by El Khoudary and published in 2019, spelled out the distinction directly. The perimenopause effect was subtle. It showed up as the absence of a learning effect, not as a drop. As the report puts it, even in perimenopause, test scores did not drop. They simply did not improve during that stage.

Not getting better and getting worse are different things. What was measured during the transition was a temporary loss of the usual improvement with practice, and it recovered afterward.

The same report noted that approximately 60 percent of midlife women report problems with memory during the transition. So both facts hold at once. The complaint is common and real. The measured change is modest and appears to be temporary. Researchers reviewing this literature have described these changes as occurring without indicating neurodegenerative disease.

If you're in your 40s and worried that losing words means something is going badly wrong, this is the most relevant finding available, and it is a reassuring one.

Not every study agrees, and that's worth knowing

It would be easy to present SWAN as the final word. It isn't, and the literature is honest about that.

In a 2010 follow-up paper in the American Journal of Epidemiology, Greendale and colleagues summarized the small body of longitudinal research available at the time. Two of three published longitudinal studies corroborated women's perceptions. The Kinmen Women-Health Investigation found a perimenopause-related deficit in verbal memory. A two-year substudy at SWAN's Chicago site found that processing speed and working memory were unaffected by the transition. The larger four-year analysis across all seven SWAN sites found the transient decrement described above.

A 2023 structured review in Frontiers in Aging Neuroscience noted that there has been insufficient research to determine whether these effects are time-limited, and suggested that studies with more repeated assessments across a wider age span would help settle the question.

The fairest summary is that the best evidence points toward a modest, domain-specific, probably temporary effect, with some disagreement between studies about exactly which domains are affected.

The mechanism question: is it just hormones?

The obvious explanation is estrogen. Estrogen acts on the brain, including regions involved in memory, and its levels fluctuate and then decline across the transition. That is a plausible mechanism, and it is where most marketing starts.

The evidence complicates it. An earlier cross-sectional SWAN analysis by Luetters and colleagues, published in the Journal of Women's Health in 2007, volume 16, pages 331 to 344, examined whether menopause stage and circulating levels of estradiol and follicle-stimulating hormone were related to cognitive performance. The title states the result: they were not.

That was a cross-sectional analysis, so it can't rule out effects that show up over time within individuals. But it does mean the simple story, where a lower estrogen number on a blood test equals worse memory, isn't supported by that data. The transition is clearly involved in some way, since the effect appears during perimenopause and resolves after it. Exactly how is not settled.

What SWAN points to as contributors

This is the part of the research that usually gets skipped, and it is arguably the most useful.

SWAN's own published guidance on memory and cognition notes that sleep and mood problems increase during the menopause transition. It states plainly that lack of sleep is linked to poor memory and difficulty focusing, and that depression and anxiety impair effort and performance on cognitive testing. SWAN women with depressive symptoms performed less well on tests of processing speed.

The 2019 progress report found that among women who had no anxiety before the transition, anxiety symptoms became more likely across it, rising from early to late perimenopause and then declining after menopause. It also found that perceived health below very good, and at least one upsetting life event in the past year, carried greater risk of anxiety symptoms than menopause stage did. Life circumstances mattered at least as much as hormonal stage.

Put those together and a practical picture emerges. Several things that impair thinking become more common during exactly this window. Sleep gets disrupted, including by night sweats. Anxiety becomes more likely. Mood shifts. Each of these independently makes it harder to concentrate and remember. Whether they fully explain the cognitive effect or sit alongside a direct hormonal one is still being worked out. But they are real, they are measurable, and unlike estrogen levels, many of them can be addressed directly.

Separating the transition from aging

There is a second thing happening in midlife, and it's easy to confuse with the first.

SWAN has also tracked cognitive aging beyond the transition. According to SWAN's published summaries, age-related declines appear in processing speed in the early 50s, in memory around age 58, and in working memory around age 61. The transition-related memory changes appear to be reversible, while persistent declines only become apparent well after menopause.

The rate of that longer-term decline isn't the same for everyone. SWAN reports that financial hardship was consistently associated with accelerated cognitive decline. Diabetes, elevated fasting glucose, central obesity, hypertension, and poor heart health were associated with the rate of decline in processing speed.

That list is notable for what's on it. The factors associated with how quickly thinking slows with age are largely cardiometabolic and social, not nutritional gaps that a capsule would close. SWAN is careful here too. Its guidance notes that controlling blood pressure, glucose, and weight is important for overall health, and that whether controlling them also lessens cognitive decline is being tested in ongoing clinical trials. That is the right level of confidence, and it's a higher standard than most brain supplements hold themselves to.

Where marketing enters

The gap between a common, distressing, poorly defined complaint and a modest, temporary, multi-factor explanation is exactly the space supplement marketing fills. So it's worth checking the most common claims against the most rigorous evidence available.

Ginkgo biloba. Ginkgo is the most studied memory supplement in the world, and it has been tested in the largest trial of its kind. The Ginkgo Evaluation of Memory study, co-funded by several arms of the US National Institutes of Health, followed 3,069 community-dwelling older adults with normal cognition or mild cognitive impairment. Participants took 120 milligrams of ginkgo extract twice daily or a placebo, across four clinical sites over eight years.

The primary results, published by DeKosky and colleagues in JAMA in 2008, volume 300, pages 2253 to 2262, found ginkgo did not reduce the incidence of dementia or Alzheimer's disease. A secondary analysis by Snitz and colleagues in JAMA in 2009, volume 302, pages 2663 to 2670, followed participants for a median of 6.1 years and found ginkgo did not slow the rate of cognitive decline.

This trial studied older adults, not women in midlife, which limits how directly it applies. But it is the most rigorous test ever run on the most heavily marketed memory supplement, and it found nothing. If ginkgo had a meaningful effect on memory, a trial of that size and length was well placed to detect it.

Creatine. Creatine has become a popular brain fog recommendation, especially for midlife women, and we've covered the evidence in detail elsewhere. The short version: the European Food Safety Authority's expert panel reviewed 21 human intervention studies in 2024 and concluded that a cause-and-effect relationship between creatine supplementation and improved cognitive function had not been established. The mechanism is plausible. The trial evidence isn't there yet.

Magnesium. Magnesium, particularly the L-threonate form, is marketed for menopausal cognitive symptoms. The researchers running a clinical trial currently investigating magnesium L-threonate for menopausal symptoms state in their own trial registration that research on its effect on overall menopausal symptoms is rare. Products are being sold on a question the investigators themselves describe as largely open.

We sell creatine and a magnesium complex that includes L-threonate. None of the above changes the reasons they can be worth taking, which we've written about separately. But neither is an established treatment for brain fog, and we're not going to describe them that way.

Why mechanism isn't enough

Every product above has a plausible mechanism. Ginkgo affects blood flow. Creatine supports cellular energy in the brain. Magnesium participates in nerve signaling. Estrogen acts on memory regions. All of this is real biology.

In each case, the step from "this is involved in the relevant biology" to "taking this improves the thing people actually care about" either failed when it was tested or hasn't been tested well. That step is the entire difference between mechanism and marketing. A mechanism tells you something might work. Only a controlled trial tells you whether it does. In this area, the trials that exist have mostly been disappointing, and the complaint being targeted is common enough and vague enough that a product can sell well without ever closing that gap.

What's worth doing instead

Based on what SWAN and related research actually identify, the more defensible priorities are fairly unglamorous.

Treat sleep as a cognitive issue, not just a comfort issue. SWAN's guidance links lack of sleep directly to poor memory and trouble focusing. If night sweats or insomnia are breaking up your nights, that's worth raising with a clinician, and it may do more for your thinking than any supplement.

Take mood and anxiety seriously. Depressive symptoms were associated with slower processing speed in SWAN, and anxiety becomes more likely across the transition. Both are treatable, and treating them is likely to help cognition along the way.

Keep an eye on the cardiometabolic basics that SWAN associates with long-term decline, including blood pressure, glucose, and central weight, while understanding that the trials testing whether controlling them protects cognition are still running.

Hormone therapy is a separate medical decision with its own body of evidence. It belongs in a conversation with a clinician, not in a supplement brand's blog, so we're leaving it out here.

And watch for the one pattern SWAN specifically flags. Its guidance advises that if memory changes come on suddenly, they should be reported to a primary care provider. Gradual, on-and-off word-finding trouble in your late 40s fits the research pattern described above. A sudden change doesn't, and deserves a proper evaluation.

The honest summary

Brain fog in midlife is a real and common experience. Around 60 percent of women report memory problems during the menopause transition, according to SWAN.

The best longitudinal evidence, SWAN's four-year study of 2,362 women, found a modest effect. During late perimenopause, women didn't show the usual improvement with repeated testing, and that improvement came back after menopause. Scores didn't fall. They stopped rising, temporarily. Not every study agrees on which cognitive domains are affected, and researchers note that more work is needed to confirm the effect is time-limited.

The mechanism isn't as simple as circulating estrogen, which SWAN found was not related to cognitive performance in a cross-sectional analysis. The factors SWAN does identify, including disrupted sleep, anxiety, depressive symptoms, and life stress, are common during this window and can be addressed.

Against that background, the most marketed products don't hold up well. The largest trial of ginkgo found no effect on dementia or cognitive decline. EFSA found cause and effect not established for creatine and cognition. Researchers studying magnesium L-threonate for menopausal symptoms describe the existing research as rare.

That's a less exciting message than most brain fog content offers, and a more useful one. The measured change is smaller than the fear around it. Much of what drives the experience is sleep, mood, and stress. And right now the evidence supports addressing those directly more than it supports buying anything, including from us.